Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26295710 | 0.82 | HRH3 (0.43) | CYP2C19CYP3A4KDM4EALDH1A1ALOX15 | |
| SCHEMBL24838146 | 0.79 | HRH3 (0.41) | CYP2C19CYP3A4KDM4EALDH1A1ALOX15 | |
| SCHEMBL25605133 | 0.79 | HRH3 (0.41) | CYP2C19CYP3A4KDM4EALDH1A1ALOX15 | |
| SCHEMBL25605129 | 0.79 | HRH3 (0.41) | CYP2C19CYP3A4KDM4EALDH1A1ALOX15 | |
| SCHEMBL25631008 | 0.79 | HRH3 (0.40) | CYP2C19KDM4EALDH1A1TP53CYP2C9 | |
| SCHEMBL25605834 | 0.79 | HRH3 (0.40) | CYP2C19KDM4EALDH1A1TP53CYP2C9 | |
| SCHEMBL25029130 | 0.77 | FPR3 (0.36) | OPRL1KDM4EALDH1A1ALOX15SIGMAR1 | |
| SCHEMBL26059633 | 0.77 | FPR3 (0.36) | OPRL1KDM4EALDH1A1ALOX15SIGMAR1 | |
| SCHEMBL25030230 | 0.77 | FPR3 (0.36) | OPRL1KDM4EALDH1A1ALOX15SIGMAR1 | |
| SCHEMBL25631005 | 0.75 | KDM4E (0.52) | CYP2C19KDM4EALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | OPRL1 4834/4885OPRM1 4706/4885CYP2C19 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.